Vaxcyte Historical Financial Statements

Stocks . USA . 
Stock . Vaxcyte
PCVX Stock  USD 57.24  -0.08  -0.14%   
Vaxcyte discloses its performance through quarterly and annual statements used to model future cash flows. Performance benchmarked against historical norms is reflected in the key metrics below:
 Gross Profit
-75 M
 Market Capitalization
8.5 B
 Earnings Share
-5.63
The one hundred twenty fundamental trends available for Vaxcyte cover valuation, profitability, and capital structure dimensions. Evaluating Vaxcyte's most recent numbers in the context of performance from 2010 to 2026 helps distinguish cyclical fluctuations from structural shifts. Per market data dated April 30, 2026, Market Cap has contracted to approximately 4.1 B. In addition to that, Enterprise Value has softened to approximately 3.9 B.
Vaxcyte's financials reflect Interest Income of 125.7 M, Depreciation And Amortization of 26.1 M, and Interest Expense of 0.0 across balance sheet and income data.
  
Vaxcyte's competitive standing is reflected in Vaxcyte Correlation. Competitive dynamics are reflected in the correlation structure.
The fundamentals of trading Vaxcyte Stock are covered in our How to Buy Vaxcyte walkthrough.

Balance Sheet Accounts

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.2 B3 B784.7 M
Moderate Growth
Short and Long Term Debt Total240.3 M228.8 M38.9 M
Moderate Growth
Other Current Liabilities135.2 M128.7 M33 M
Moderate Growth
Total Current Liabilities216 M205.8 M51.5 M
Moderate Growth
Other Liabilities7.7 K8.1 K142 K
Consistent Decline
Property Plant And Equipment Net516.3 M491.7 M87.7 M
Moderate Growth
Accounts Payable74.4 M70.9 M16.2 M
Moderate Growth
Cash294.6 M174 M174 M
Moderate Growth
Non Current Assets Total1.5 B1.4 B300.8 M
Moderate Growth
Non Current Assets Other482.6 K508 K7.1 M
High Variability
Other Assets1.091.15866.5 K
High Variability
Long Term Debt384.8 K405 K2.2 M
Consistent Decline
Cash And Short Term Investments1.6 B1.6 B470.9 M
Consistent Growth
Common Stock Shares Outstanding70.8 M136.1 M39.7 M
Consistent Growth
Long Term Debt Total384.8 K405 K2.2 M
Consistent Decline
Liabilities And Stockholders Equity3.2 B3 B784.7 M
Moderate Growth
Non Current Liabilities Total162.4 M154.7 M43.9 M
Moderate Growth
Capital Surplus703.8 M670.3 M250.5 M
Consistent Growth
Other Current Assets20.8 M19.8 M6 M
Consistent Growth
Other Stockholder Equity5.1 B4.8 B1.1 B
Moderate Growth
Total Liabilities378.5 M360.5 M95.4 M
Moderate Growth
Total Current Assets1.7 B1.6 B483.9 M
Consistent Growth
Short Term Debt4.3 M6.1 M2.5 M
Moderate Growth
Common Stock69.8 K134 K40.2 K
Consistent Growth
Property Plant Equipment38.2 M36.4 M14.1 M
Consistent Growth
Common Stock Total Equity33.8 K64.4 K25.7 K
Moderate Growth
Capital Stock77.7 K134 K40.6 K
Consistent Growth
Non Current Liabilities Other85.5 K90 K1.8 M
Consistent Decline
Net Working Capital770.3 M1.4 B403.1 M
Moderate Growth
Net Receivables48.9 M46.6 M7.3 M
Moderate Growth
Property, Plant and Equipment (Gross)550.7 M524.5 M101.3 M
Moderate Growth
Deferred Long Term Liabilities403.3 K575 K239.9 K
Moderate Growth

Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income125.7 M119.7 M25.3 M
Moderate Growth
Depreciation And Amortization26.1 M24.9 M5.8 M
Moderate Growth
Selling General Administrative135.8 M129.4 M32.6 M
Moderate Growth
Other Operating Expenses969.9 M923.7 M210.9 M
Moderate Growth
Research Development834 M794.3 M172.8 M
Moderate Growth
Total Operating Expenses969.9 M923.7 M210.8 M
Moderate Growth
Total Other Income Expense Net164.9 M157 M30.6 M
Moderate Growth
Net Interest Income125.7 M119.7 M25.6 M
Moderate Growth
Cost Of Revenue16.6 M18.2 M8.7 M
High Variability
Reconciled Depreciation26.1 M24.9 M6 M
Moderate Growth
Non Operating Income Net Other2.2 M4.1 M1.5 M
Moderate Growth
Selling And Marketing Expenses8.1 M9.2 M10 M
Stable

Cash Flow Statement Items

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.7 M1.8 M27.5 M
Moderate Decline
Stock Based Compensation145.8 M138.8 M27.1 M
Moderate Growth
Begin Period Cash Flow273.8 M389.2 M147.9 M
Moderate Growth
Other Cashflows From Financing Activities1.9 M2 M14.3 M
High Variability
Depreciation26.1 M24.9 M5.5 M
Moderate Growth
Capital Expenditures14.7 M13.7 M8 M
High Variability
Total Cash From Financing Activities1.9 M2 M261.8 M
High Variability
End Period Cash Flow290.9 M175.4 M157.1 M
Moderate Growth
Change To Account Receivables853.6 K781.2 K1.1 M
Consistent Decline
Dividends Paid299.2 K336.6 K367.4 K
Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.520.55161.8129
High Variability
Payables Turnover0.05150.05420.2356
Consistent Decline
Cash Per Share13.8111.470111.6314
High Variability
Days Payables Outstanding7.3 K7 K3.7 K
Consistent Growth
Income Quality0.970.85510.8796
Moderate Variation
Current Ratio8.247.90949.4505
High Variability
Capex Per Share0.180.10080.1309
High Variability
Interest-Bearing Debt Per Share1.771.68150.8962
High Variability
Debt To Assets0.04240.07510.0704
Moderate Decline
Days Of Payables Outstanding7.3 K7 K3.7 K
Consistent Growth
Ebt Per Ebit1.00.830.9364
Stable
Long Term Debt To Capitalization0.08150.04580.0749
Moderate Decline
Quick Ratio8.247.90949.4505
High Variability
Cash Ratio0.80.84557.1404
High Variability
Free Cash Flow Operating Cash Flow Ratio0.851.02091.0588
Stable
Debt Ratio0.04240.07510.0704
Moderate Decline

Valuation Indicators

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.1 B6.3 B2.8 B
Moderate Growth
Enterprise Value3.9 B6.3 B2.7 B
Moderate Growth

Core Fundamental Drivers

Methodology, Assumptions & Data Sources

This time-series reference data for Vaxcyte's financial indicators helps evaluate directional changes in the company's underlying fundamentals. Vaxcyte has a market cap of 8.48 B, ROE of -25.59%.

Reported values for Vaxcyte are derived from periodic company reporting and market reference feeds and standardized for analysis. Professional analyst research is incorporated when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.